Management of restless legs syndrome by the partial D2-agonist terguride
| Autor: | Karel Sonka, Karel Kranda, M. Pretl |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Agonist
Adult Male medicine.medical_specialty Self-Assessment medicine.drug_class Terguride Restless Legs Syndrome mental disorders medicine Humans Restless legs syndrome Lisuride Aged D2 agonist business.industry Receptors Dopamine D2 Dopaminergic General Medicine Middle Aged medicine.disease Treatment Outcome Nocturnal sleep Anesthesia Dopamine Agonists Physical therapy Female Sleep Stages business Sleep medicine.drug |
| Zdroj: | Sleep medicine. 4(5) |
| ISSN: | 1389-9457 |
| Popis: | Background : Terguride as a partial D2-receptors agonist seems suitable for treatment of restless legs syndrome (RLS). Methods : Nine RLS patients without previous dopaminergic therapy received a daily dose of terguride (0.25 mg) 29.9±16.9 (SD) days. Results : Two patients enrolled in the study failed to turn up for a successive check up. The seven subjects who were re-examined complied with the therapy. Their RLS symptoms improved (as measured on the International RLS intensity scale), decreasing from 24.3±5.3 to 14±4.7 ( p =0.014). However, the terguride treatment did not significantly alter the daytime sleepiness or the subjective duration of nocturnal sleep. The daily dose was doubled in three patients who reported insufficient RLS improvement. One of the three patients later reported augmentation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect